BIOMAT Database Logo BIOMAT Database Logo

Blood phenytoin concentrations produced by ingestion of three different phenytoin preparations. 1972

D B Appleton, and M J Eadie, and W D Hooper, and B Lucas, and J M Sutherland, and J H Tyrer

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010592 Pharmaceutic Aids Substances which are of little or no therapeutic value, but are necessary in the manufacture, compounding, storage, etc., of pharmaceutical preparations or drug dosage forms. They include SOLVENTS, diluting agents, and suspending agents, and emulsifying agents. Also, ANTIOXIDANTS; PRESERVATIVES, PHARMACEUTICAL; COLORING AGENTS; FLAVORING AGENTS; VEHICLES; EXCIPIENTS; OINTMENT BASES. Aids, Pharmaceutic,Aids, Pharmaceutical,Pharmaceutical Aids
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D002118 Calcium A basic element found in nearly all tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes. Coagulation Factor IV,Factor IV,Blood Coagulation Factor IV,Calcium-40,Calcium 40,Factor IV, Coagulation
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004339 Drug Compounding The preparation, mixing, and assembly of a drug. (From Remington, The Science and Practice of Pharmacy, 19th ed, p1814). Drug Formulation,Drug Preparation,Drug Microencapsulation,Pharmaceutical Formulation,Compounding, Drug,Formulation, Drug,Formulation, Pharmaceutical,Microencapsulation, Drug,Preparation, Drug
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D004833 Epilepsy, Temporal Lobe A localization-related (focal) form of epilepsy characterized by recurrent seizures that arise from foci within the TEMPORAL LOBE, most commonly from its mesial aspect. A wide variety of psychic phenomena may be associated, including illusions, hallucinations, dyscognitive states, and affective experiences. The majority of complex partial seizures (see EPILEPSY, COMPLEX PARTIAL) originate from the temporal lobes. Temporal lobe seizures may be classified by etiology as cryptogenic, familial, or symptomatic. (From Adams et al., Principles of Neurology, 6th ed, p321). Epilepsy, Benign Psychomotor, Childhood,Benign Psychomotor Epilepsy, Childhood,Childhood Benign Psychomotor Epilepsy,Epilepsy, Lateral Temporal,Epilepsy, Uncinate,Epilepsies, Lateral Temporal,Epilepsies, Temporal Lobe,Epilepsies, Uncinate,Lateral Temporal Epilepsies,Lateral Temporal Epilepsy,Temporal Lobe Epilepsies,Temporal Lobe Epilepsy,Uncinate Epilepsies,Uncinate Epilepsy
D005260 Female Females

Related Publications

D B Appleton, and M J Eadie, and W D Hooper, and B Lucas, and J M Sutherland, and J H Tyrer
Plasma phenytoin levels produced by various phenytoin preparations.
October 1975, The Medical journal of Australia,
D B Appleton, and M J Eadie, and W D Hooper, and B Lucas, and J M Sutherland, and J H Tyrer
Clinical significance of generic inequivalence of three different pharmaceutical preparations of phenytoin.
January 1974, European journal of clinical pharmacology,
D B Appleton, and M J Eadie, and W D Hooper, and B Lucas, and J M Sutherland, and J H Tyrer
Level dose ratio and the threshold of intoxication level by dosages of three different phenytoin preparations.
September 1989, The Japanese journal of psychiatry and neurology,
D B Appleton, and M J Eadie, and W D Hooper, and B Lucas, and J M Sutherland, and J H Tyrer
Bioavailability of phenytoin: comparison between three preparations.
April 1985, Israel journal of medical sciences,
D B Appleton, and M J Eadie, and W D Hooper, and B Lucas, and J M Sutherland, and J H Tyrer
BLOOD LEVELS PRODUCED BY THREE ORAL THEOPHYLLINE-CONTAINING PREPARATIONS: DOUBLE-BLIND CROSSOVER STUDY.
April 1964, New York state journal of medicine,
D B Appleton, and M J Eadie, and W D Hooper, and B Lucas, and J M Sutherland, and J H Tyrer
Crystallization of three phenytoin preparations in intravenous solutions.
April 1982, American journal of hospital pharmacy,
D B Appleton, and M J Eadie, and W D Hooper, and B Lucas, and J M Sutherland, and J H Tyrer
Comparative study of bioavailabilities of different phenytoin preparations.
January 1982, Brain & development,
D B Appleton, and M J Eadie, and W D Hooper, and B Lucas, and J M Sutherland, and J H Tyrer
[Ophthalmoplegia produced by phenytoin].
November 2009, Neurologia (Barcelona, Spain),
D B Appleton, and M J Eadie, and W D Hooper, and B Lucas, and J M Sutherland, and J H Tyrer
Corneal epitheliotrophic capacity of three different blood-derived preparations.
June 2006, Investigative ophthalmology & visual science,
D B Appleton, and M J Eadie, and W D Hooper, and B Lucas, and J M Sutherland, and J H Tyrer
Phenytoin toxicity produced by tolbutamide.
December 1988, BMJ (Clinical research ed.),
Copied contents to your clipboard!